Startup | October 15, 2021
AUM Biosciences closes US $ 27 million `Series A’ funding round
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Subscribe To Our Newsletter & Stay Updated
